Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,506 JPY | +3.51% | +1.72% | -10.68% |
04-25 | Transcript : Astellas Pharma Inc., 2024 Earnings Call, Apr 25, 2024 | |
04-25 | Astellas Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company is one of the best yield companies with high dividend expectations.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 141.3 times its estimated earnings per share for the ongoing year.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.68% | 17.15B | A | ||
+26.08% | 661B | C+ | ||
+26.74% | 566B | B | ||
-6.57% | 352B | C+ | ||
+18.70% | 332B | B- | ||
+3.71% | 283B | C+ | ||
+13.43% | 231B | B+ | ||
+4.71% | 200B | B- | ||
-9.53% | 195B | A+ | ||
-4.29% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4503 Stock
- Ratings Astellas Pharma Inc.